[Early therapeutic intervention in heart failure].

Area of Science:

• Cardiology and Cardiovascular Diseases
• Pharmacology and Therapeutics

Context:

• Despite advances in treating moderate to severe heart failure with vasodilators, digitalis, and diuretics, mortality rates remain high.
• Left ventricular hypertrophy (LVH) is a primary early pathophysiological change in heart failure, linked to hypertension, coronary artery disease, aging, and obesity.
• LVH can progress to diastolic/systolic heart failure, ischemia, arrhythmias, and sudden cardiac death.

Purpose:

• To investigate the potential benefits of initiating treatment at earlier stages of heart failure.
• To explore the role of angiotensin-converting enzyme (ACE) inhibitors in reducing left ventricular hypertrophy (LVH).
• To evaluate if early intervention with ACE inhibitors in asymptomatic heart failure patients improves prognosis, as suggested by SAVE and SOLVD-prevention trials.

Summary:

• ACE inhibitors have demonstrated the ability to reduce LVH within one month.
• Large trials like SAVE and SOLVD-prevention are assessing the efficacy of early ACE inhibitor treatment in asymptomatic heart failure.
• This strategy aims to improve patient outcomes by intervening before significant disease progression.

Impact:

• Early intervention targeting LVH with ACE inhibitors could significantly reduce heart failure mortality and morbidity.
• This approach may shift treatment paradigms towards proactive management of cardiovascular risk factors.
• Findings from ongoing trials will inform clinical guidelines for managing early-stage heart failure and related conditions.